Vanguard Group
TRVI icon

Vanguard Group’s Trevi Therapeutics TRVI Stock Holding History

Vanguard Group’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$80.6M Buy
6,434,655
+607,669
+10% +$7.02M ﹤0.01% 1953
2025
Q3 		$53.3M Buy
5,826,986
+510,295
+10% +$3.83M ﹤0.01% 2122
2025
Q2 		$29.1M Buy
5,316,691
+1,478,659
+39% +$9.2M ﹤0.01% 2379
2025
Q1 		$24.1M Buy
3,838,032
+328,819
+9% +$1.57M ﹤0.01% 2426
2024
Q4 		$14.5M Buy
3,509,213
+246,832
+8% +$790K ﹤0.01% 2753
2024
Q3 		$10.9M Buy
3,262,381
+824,930
+34% +$2.45M ﹤0.01% 2911
2024
Q2 		$7.26M Buy
2,437,451
+133,803
+6% +$372K ﹤0.01% 3080
2024
Q1 		$7.95M Buy
2,303,648
+60,249
+3% +$134K ﹤0.01% 3092
2023
Q4 		$3.01M Buy
2,243,399
+285,524
+15% +$432K ﹤0.01% 3455
2023
Q3 		$4.27M Buy
1,957,875
+44,613
+2% +$101K ﹤0.01% 3315
2023
Q2 		$4.57M Buy
1,913,262
+413,511
+28% +$1.04M ﹤0.01% 3348
2023
Q1 		$2.77M Buy
1,499,751
+60,158
+4% +$136K ﹤0.01% 3559
2022
Q4 		$2.78M Buy
1,439,593
+115,216
+9% +$227K ﹤0.01% 3544
2022
Q3 		$2.04M Buy
1,324,377
+1,087,437
+459% +$3.57M ﹤0.01% 3734
2022
Q2 		$666K Buy
236,940
+84,109
+55% +$207K ﹤0.01% 4212
2022
Q1 		$336K Buy
152,831
+10,780
+8% +$11.2K ﹤0.01% 4456
2021
Q4 		$111K Buy
142,051
+5,502
+4% +$5.77K ﹤0.01% 4607
2021
Q3 		$192K Buy
136,549
+3,334
+3% +$5.9K ﹤0.01% 4490
2021
Q2 		$300K Hold
133,215
– – ﹤0.01% 4328
2021
Q1 		$361K Hold
133,215
– – ﹤0.01% 4181
2020
Q4 		$322K Hold
133,215
– – ﹤0.01% 4030
2020
Q3 		$537K Sell
133,215
-5,700
-4% -$26.8K ﹤0.01% 3802
2020
Q2 		$914K Sell
138,915
-11,517
-8% -$40.5K ﹤0.01% 3636
2020
Q1 		$495K Hold
150,432
– – ﹤0.01% 3673
2019
Q4 		$564K Hold
150,432
– – ﹤0.01% 3772
2019
Q3 		$677K Buy
150,432
+32,341
+27% +$176K ﹤0.01% 3748
2019
Q2 		$886K Buy
+118,091
New +$1.02M ﹤0.01% 3706

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group's TRVI Position: Q4 2025 in Review

Vanguard Group increased its Trevi Therapeutics (TRVI) stake by 10% in Q4 2025, buying an estimated $7.02M and bringing the position to 6,434,655 shares worth $80.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1953.

Vanguard Group first reported a position in TRVI in Q2 2019 and has held it in 27 quarters since. 184 funds tracked by Wall St. Rank hold TRVI as of Q4 2025.

  • Vanguard Group held 6,434,655 shares of Trevi Therapeutics worth $80.6M as of Q4 2025.
  • Vanguard Group bought 607,669 Trevi Therapeutics shares in Q4 2025, an estimated $7.02M.
  • Trevi Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #1953 holding.
  • Vanguard Group first reported a position in Trevi Therapeutics in Q2 2019 and has held it in 27 quarters since.
  • 184 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.